keyword
MENU ▼
Read by QxMD icon Read
search

metoclopramide AND delayed CINV

keyword
https://www.readbyqxmd.com/read/25960846/a-comparison-of-5-ht3-receptor-antagonist-and-metoclopramide-in-the-patients-receiving-chemotherapeutic-regimens-including-cmf-caf-and-chop
#1
Kazem Anvari, Mehdi Seilanian-Toussi, Hossein Hosseinzad-Ashkiki, Soodabeh Shahidsales
BACKGROUND: Chemotherapy- induced nausea and vomiting (CINV) occur frequently causing problems with an unacceptably high incidence that significantly affect patients' daily functioning and health-related quality of life. The present study was aimed to compare acute CINV for granisetron as 5-HT3 receptor antagonist and metoclopramide in the patients receiving chemotherapeutic regimens including cyclophosphamide and adriamycin. An attempt is made to examine whether it is possible to successfully replace granisetron with metoclopramide in control of acute CINV...
March 2015: Iranian Journal of Cancer Prevention
https://www.readbyqxmd.com/read/25032030/olanzapine-an-antiemetic-option-for-chemotherapy-induced-nausea-and-vomiting
#2
REVIEW
Megan V Brafford, Ashley Glode
Despite the appropriate use of pharmacologic and nonpharmacologic preventative measures, chemotherapy-induced nausea and vomiting (CINV) can be debilitating and can decrease quality of life for many patients. In addition, patients may be unwilling to continue chemotherapy treatment due to the uncontrollable nausea and vomiting associated with their therapy. Refractory CINV can occur at any point in a treatment cycle, despite adequate therapy for acute and delayed CINV. Current prevention strategies include using serotonin (5-HT3) receptor antagonists, corticosteroids, and/or neurokinin-1 receptor antagonists...
January 2014: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/24748417/addition-of-aprepitant-improves-protection-against-cisplatin-induced-emesis-when-a-conventional-anti-emetic-regimen-fails
#3
Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han
OBJECTIVE: We investigated whether aprepitant, a neurokinin-1 antagonist, could decrease chemotherapy-induced nausea and vomiting (CINV) following cisplatin, when a conventional anti-emetic regimen had failed. METHODS: This was a prospective study (April 2011-April 2012) of patients with lung cancer, treated with cisplatin at the Beijing Cancer Hospital, and initially receiving granisetron, dexamethasone, and metoclopramide as anti-emetics. If patients experienced vomiting of grade ≥2 and required rescue anti-emetic medications during the first cycle, oral aprepitant was added in subsequent cycles (day 1: 125 mg; days 2-3: 80 mg once daily)...
June 2014: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/23448741/ginger-as-an-antiemetic-modality-for-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis
#4
REVIEW
Jiyeon Lee, Heeyoung Oh
PURPOSE/OBJECTIVES: To evaluate the effect of ginger as an antiemetic modality for the control of chemotherapy-induced nausea and vomiting (CINV). DATA SOURCES: Databases searched included MEDLINE® (PubMed), Embase, CINAHL®, Cochrane Central Register of Controlled Trials, Korean Studies Information Service System, Research Information Sharing Service by the Korean Education and Research Information Service, and Dissertation Central. DATA SYNTHESIS: A systematic review was conducted of five randomized, controlled trials involving 872 patients with cancer...
March 2013: Oncology Nursing Forum
https://www.readbyqxmd.com/read/22663171/assessment-of-the-relationship-between-adherence-with-antiemetic-drug-therapy-and-control-of-nausea-and-vomiting-in-breast-cancer-patients-receiving-anthracycline-based-chemotherapy
#5
Alexandre Chan, Xiu Hui Low, Kevin Yi-Lwern Yap
BACKGROUND: There are little prevalence data in the literature on nonadherence to outpatient antiemetic regimens for prophylaxis of chemotherapy-induced nausea and vomiting (CINV). It is unclear whether adherence with outpatient antiemetic regimens is associated with better CINV control. Our previous survey research supports the work of clinical pharmacists in collaborative practice with medical oncologists in improving adherence with antiemetic therapy in women undergoing highly emetic chemotherapy for breast cancer...
June 2012: Journal of Managed Care Pharmacy: JMCP
https://www.readbyqxmd.com/read/20824481/antiemetics-in-children-receiving-chemotherapy-mascc-esmo-guideline-update-2009
#6
Karin Jordan, Fausto Roila, Alexander Molassiotis, Ernesto Maranzano, Rebecca A Clark-Snow, Petra Feyer et al.
Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT(3) receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the 5-HT(3) receptor antagonists ondansetron and granisetron. The new 5-HT(3) receptor antagonist palonosetron was evaluated in one comparative study so far showing promising activity. Combinations of a 5-HT(3) receptor antagonist and dexamethasone showed increased efficacy with respect to a 5-HT(3) receptor antagonist alone...
March 2011: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/19318325/-treatment-of-tumor-therapy-induced-nausea-and-vomiting
#7
REVIEW
Béla Pikó, Ali Bassam
Even today, nausea and vomiting are two of the most distressing adverse effects associated with tumor therapy. The authors give an overview of the mechanism and the trigger factors (emetogenic potential of the chemotherapies, the patient risk factors, and the used antiemetic drugs) of nausea and vomiting. A short summary will describe the antiemetic drugs focusing on metoclopramide, steroid and the currently widely used setron therapy which is effective only during the acute phase of chemotherapy-induced nausea and vomiting (CINV)...
March 2009: Magyar Onkologia
https://www.readbyqxmd.com/read/19193549/chemotherapy-induced-nausea-and-vomiting-challenges-and-opportunities-for-improved-patient-outcomes
#8
REVIEW
Rebecca Hawkins, Steven Grunberg
Oncology nurses play a pivotal role in the care of patients receiving chemotherapy and are in a prime position to facilitate better care of patients experiencing chemotherapy-induced nausea and vomiting (CINV). However, to do so, they must be kept well apprised of the most recent guidelines, the latest developments in CINV therapy, and the expanding knowledge of CINV pathophysiology. In April 2008, a roundtable meeting of experts in the field of CINV was convened after a detailed needs assessment revealed a knowledge gap in CINV management on the part of oncology nurses...
February 2009: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/18839220/palonosetron-aloxi-and-dexamethasone-for-the-prevention-of-acute-and-delayed-nausea-and-vomiting-in-patients-receiving-multiple-day-chemotherapy
#9
Maurizio Musso, Renato Scalone, Vincenza Bonanno, Alessandra Crescimanno, Vita Polizzi, Ferdinando Porretto, Carlo Bianchini, Tania Perrone
OBJECTIVE: The objective of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple-day chemotherapy and the efficacy of a second dose of palonosetron in treating breakthrough emesis. MATERIALS AND METHODS: Forty-six patients treated with multiple-day chemotherapy for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of chemotherapy and dexamethasone throughout the entire period of chemotherapy...
February 2009: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/18391612/chemotherapy-induced-nausea-and-vomiting
#10
REVIEW
Lisa Lohr
Chemotherapy-induced nausea and vomiting (CINV) affects many cancer patients and has a great influence on quality of life. CINV involves coordination of several organs of the gastrointestinal tract, the peripheral and central nervous systems. Many neurotransmitters are involved in this process, and the predominant receptors are serotonin, neurokinin-1 and dopamine receptors. Risk factors for CINV include patient gender and age, past history of CINV, plus the emetogenicity and administration schedule of chemotherapy...
March 2008: Cancer Journal
https://www.readbyqxmd.com/read/17239326/prevention-of-emesis-from-multiple-day-and-high-dose-chemotherapy-regimens
#11
REVIEW
Rudolph M Navari
The prevention of chemotherapy-induced nausea and vomiting (CINV) has improved significantly with the introduction of the 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists combined with dexamethasone. Most studies have reported on patients undergoing single-day highly or moderately emetogenic chemotherapy. There have been fewer studies and much less success in preventing CINV in patients undergoing multiple-day chemotherapy or high-dose chemotherapy with stem cell transplant. Current practice guidelines suggest the use of a first-generation 5-HT3 receptor antagonist and dexamethasone daily for each day of the multiple-day chemotherapy regimens...
January 2007: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/16977460/skipping-day-2-antiemetic-medications-may-improve-chemotherapy-induced-delayed-nausea-and-vomiting-control-results-of-two-pilot-phase-ii-trials
#12
Paula P Lajolo, Auro del Giglio
BACKGROUND: 5HT-3 antagonists and corticosteroids control less than 50% of delayed chemotherapy induced nausea and vomiting (CINV) episodes. MATERIALS AND METHODS: Two pilot phase II studies were conducted at our institution in which all patients received ondansetron 16 mg and dexamethasone 20 mg before highly and moderately emetogenic chemotherapy on day 1. Patients on study 1 received metoclopramide 10 mg PO q8 h, granisetron 0.5 mg PO QD and dexamethasone 8 mg QD on days 2 and 3, whereas only metoclopramide was continued on the same schedule on day 4...
March 2007: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/15352652/pathogenesis-based-treatment-of-chemotherapy-induced-nausea-and-vomiting-two-new-agents
#13
REVIEW
Rudolph M Navari
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors (female gender, younger age, alcohol consumption, history of motion sickness) are the major risk factors for CINV. The use of 5-hydroxytryptamine3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of acute CINV, but delayed nausea and vomiting remains a significant clinical problem...
July 2003: Journal of Supportive Oncology
https://www.readbyqxmd.com/read/12956617/options-for-the-prevention-and-management-of-acute-chemotherapy-induced-nausea-and-vomiting-in-children
#14
REVIEW
L Lee Dupuis, Paul C Nathan
The current standard of care with respect to preventing acute chemotherapy-induced nausea and vomiting (CINV) in children includes the administration of a 5-HT(3) antagonist with or without a corticosteroid, depending on the emetogenicity of the chemotherapy to be given. Problems in assessing the emetogenicity of chemotherapy regimens and nausea severity in children may influence the degree of success of CINV prophylaxis. Nevertheless, the majority of children who receive chemotherapy today experience moderate to complete control of acute CINV when given appropriate antiemetic prophylaxis...
2003: Paediatric Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"